Mark Panzenbeck
Boehringer Ingelheim (United States)(US)
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Estrogen and related hormone effects, Inflammatory Bowel Disease, Immune Response and Inflammation, Immunotherapy and Immune Responses
Most-Cited Works
- → An RORγt Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn's Disease Patients(2018)47 cited
- → BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis(2018)46 cited
- → Nonsteroidal Dissociated Glucocorticoid Agonists Containing Azaindoles as Steroid A-Ring Mimetics(2010)45 cited
- → Fecal MicroRNAs Show Promise as Noninvasive Crohn’s Disease Biomarkers(2020)40 cited
- The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function.(2013)
- → BI 1002494, a Novel Potent and Selective Oral Spleen Tyrosine Kinase Inhibitor, Displays Differential Potency in Human Basophils and B Cells(2016)23 cited
- → The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease(2021)22 cited
- → Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357(2021)19 cited
- → Non-steroidal dissociated glucocorticoid agonists: indoles as A-ring mimetics and function-regulating pharmacophores(2011)19 cited
- → CCR1 Plays a Critical Role in Modulating Pain through Hematopoietic and Non-Hematopoietic Cells(2014)18 cited